NARRATIVE REVIEW2026
Retatrutide in type 2 diabetes mellitus and obesity: an overview.
Panou T, Gouveri E, Popovic DS, et al. Expert Review of Clinical Pharmacology. 2026;19(4):313-339.
What they did. The authors searched Scopus, PubMed/MEDLINE and Google Scholar and pulled together the published clinical results on retatrutide in people with type 2 diabetes, overweight or obesity, and fatty liver disease.
What they found. This is a narrative overview rather than a pooled analysis, so it reports no combined sample size. It summarizes trial reports of lower blood sugar markers, body weight, blood pressure and liver fat in study groups, and notes that mild-to-moderate stomach and bowel side effects were more frequent at the higher dose levels, which the authors link to faster dose increases. The authors conclude that more investigation is needed.
Why it matters for testing. Every result in this review comes from trial drug made by the sponsor under pharmaceutical controls. None of it tells you anything about a research-grade vial bought online, which has to be checked for identity and content on its own.
SYSTEMATIC REVIEW AND META-ANALYSIS2026
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V, et al. High Blood Pressure & Cardiovascular Prevention. 2026;33(5):503-516.
What they did. The authors searched PubMed, Cochrane Library, Scopus and ClinicalTrials.gov for randomized controlled trials of retatrutide and pooled the blood pressure and blood fat results using a random-effects model.
What they found. Across the pooled randomized trials, participants given retatrutide had lower systolic and diastolic blood pressure, total cholesterol, LDL cholesterol and triglycerides than comparison groups. HDL cholesterol showed no significant difference. The total cholesterol result showed high variability between trials. The PubMed record does not state how many trials or participants were pooled.
Why it matters for testing. A pooled analysis assumes every trial used the same well-characterised molecule at a known strength. Open-market vials carry no such assurance, so content and purity testing is needed before any vial can be compared with what was studied.
RANDOMIZED CONTROLLED TRIAL (PHASE 3)2026
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Bellido V, le Roux CW, Ekinci EI, et al. Lancet. 2026;408(10563):1455-1472.
What they did. This Lilly-funded, double-blind Phase 3 trial (TRIUMPH-2) enrolled adults with obesity and type 2 diabetes at 92 sites in eight countries and randomly assigned them to one of three retatrutide dose groups or placebo, given once a week for 80 weeks.
What they found. Of 1,152 participants randomized, 965 (84%) completed study drug. All three retatrutide groups lost more body weight than the placebo group at 80 weeks, with placebo-adjusted differences of roughly 7 to 14 percentage points (p<0.0001). Stomach and bowel side effects (diarrhoea, nausea), low blood pressure and abnormal skin sensations (dysesthesia) were more common with retatrutide, and stopping treatment because of side effects was more frequent in the two higher dose groups than with placebo.
Why it matters for testing. The trial drug was manufactured to a defined specification by the sponsor. Vials sold as "reta" outside a trial are unapproved, and their identity, strength, sterility and endotoxin level are unknown until tested.
Know what is in your vial
See every Retatrutide lot we have tested, or send yours in.
Summaries are written by Vialidate Labs from the published articles, via PubMed. Read the original papers for full methods and results. Vialidate reports analytical results only; nothing on this page is medical advice or a recommendation to use any compound.